Medical Knowledge Cockpit adenocarcinoma

 

EGFR

• Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor
• The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton
• ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas
• Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence
• Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope

• Decorin is a biological ligand for the epidermal growth factor receptor
• Role of the N-terminus of epidermal growth factor in ErbB-2/ErbB-3 binding studied by phage display
• Cloning and characterization of GRB14, a novel member of the GRB7 gene family
• A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling
• A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling
• UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug
• Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells
• The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor

 

BRAF

• BRAF V600E is a determinant of sensitivity to proteasome inhibitors
• Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation
• Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

• Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

ERBB2

• Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma
• Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas
• A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

RAD54L

• Human and mouse homologs of the Saccharomyces cerevisiae RAD54 DNA repair gene: evidence for functional conservation

MSR1

• Macrophage scavenger receptor confers an adherent phenotype to cells in culture

 

ERBB2

Somatic tumors

breast, ovarian, other tumour types, NSCLC, gastric

Tumor types germline

Cancer Syndrom

Translocation partner

Name

v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)

Chromosome banding

17q21.1

Cancer molecular gen.

Dom

Mutation type

A, Mis, O

Other syndrome disease

 

• Chronic myeloid leukemia
  Homo sapiens (human) one gene

  ---

• PI3K-Akt signaling pathway
  Homo sapiens (human) one gene

  ---

• Thyroid cancer
  Homo sapiens (human) one gene

  ---

• Vascular smooth muscle contraction
  Homo sapiens (human) one gene

  ---

• Dorso-ventral axis formation
  Homo sapiens (human) one gene

  ---

• Gap junction
  Homo sapiens (human) one gene

  ---

 

ERBB2

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. Thisprotein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bindtightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding andenhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activatedprotein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 ofisoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655,shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, includingbreast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encodingdifferent isoforms and others that have not been fully characterized. (provided by RefSeq, Jul 2008)

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases

Thisprotein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bindtightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding andenhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activatedprotein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 ofisoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655,shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, includingbreast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encodingdifferent isoforms and others that have not been fully characterized. (provided by RefSeq, Jul 2008)